ALLSTAR

Condition/Intervention:

  • Myocardial infarction

Study Name: 

ALLogeneic heart STem cells to Achieve myocardial Regeneration, ALLSTAR

Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction

Phase:

Phase1/2


Summary:

This study is to determine the safety profile and evaluate whether CAP-1002 (heart stem cells) administered into the heart of patients with inadequate blood supply (ischemic left ventricular dysfunction) and a previous heart attack (anterior myocardial infarction (MI)) may result in structural cardiac or functional clinical benefits for patients.

More medical summary: This study is to determine the safety profile and evaluate whether CAP-1002 (heart stem cells) administered by intracoronary infusion in patients with ischemic left ventricular dysfunction and a previous anterior myocardial infarction (MI) may result in structural cardiac or functional clinical benefits for patients.

Principal Investigator:

Raj Makkar, MD

Co-Investigators:

Hasanian Al-Jilaihawi, MD
Jorge Castellanos, MD
Abhijeet Dhoble, MD
Timothy Henry, MD
Mamoo Nakamura, MD


Study Coordinator and Contact:

Tracey S. Early, BS, MA, CCRP
Phone: 310-423-1231
Email: tracey.early@cshs.org


Status: Recruiting

IRB No: CR00007910/Pro00029280

Allstar - Physician Information